Medopharm, one of the major pharma firms in the nation, to import and promote the therapy. Zomer added, “It is important that we have secured Medopharm, as the importer and the marketing authorisation holder of CimetrA given their vast experience of taking medicinal products through the process to full approval for sale”.
MGC claimed it had obtained agreements for two new manufacturing sites to manage the expected rise in demand. Investors were assured that the new facilities will be utilized to produce huge commercial volumes of CimetrA until the company’s Malta production facility starts its complete operation in 2022. CimetrA is a nanoparticle concept with anti-inflammatory and immunomodulatory properties based on the spice Curcumin and the plant extract Boswellia. A phase III COVID-19 study employing the MGC therapy is now being led by Israeli experts.
